Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenylalanine + tyrosine is a combination of two essential amino acids, both of which serve as building blocks for protein synthesis and are precursors in the biosynthesis of catecholamine neurotransmitters such as dopamine, norepinephrine, and epinephrine. Phenylalanine is converted in the body to tyrosine via the enzyme phenylalanine hydroxylase. Tyrosine then serves as a precursor for several important neurotransmitters and hormones. This combination may be used in nutritional supplementation or medical foods, particularly for individuals with specific metabolic needs (e.g., certain inherited disorders). The primary clinical context involves dietary management in conditions like phenylketonuria (PKU), where patients cannot metabolize phenylalanine efficiently and may require controlled intake of these amino acids[4][5][6][7]. There is also some evidence that combined supplementation can influence mental health parameters or cognitive performance under stress[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenylalanine + tyrosine.